Bruker Corporation Commissions Novel 18 Tesla MRI in Portugal
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Bruker Corporation announced the commissioning of a novel BioSpec 18 Tesla preclinical MRI at the Champalimaud Foundation in Lisbon, Portugal. The BioSpec 18T system provides increased spatial resolution and sensitivity, enabling advanced magnetic resonance imaging and magnetic resonance spectroscopic imaging methods for cancer and neuroscience research, where characterization of tissue microstructure, and localized metabolism and dynamics are critical. Installed at the Champalimaud Foundation's preclinical MRI laboratory in Lisbon under the leadership of Professor Noam Shemesh, the BioSpec 18T supports advanced neuroscience and oncology research for in vivo studies of cancer, metastasis, brain plasticity and neural activity in preclinical models, while supporting the discovery of novel imaging biomarkers with translational relevance. The 18 Tesla system complements Champalimaud's existing 16.4 Tesla vertical-bore MRI/NMR and 9.4 Tesla horizontal-bore MRI.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BRKR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BRKR
Wall Street analysts forecast BRKR stock price to fall
12 Analyst Rating
7 Buy
4 Hold
1 Sell
Moderate Buy
Current: 54.390
Low
40.00
Averages
52.18
High
60.00
Current: 54.390
Low
40.00
Averages
52.18
High
60.00
About BRKR
Bruker Corporation is a developer, manufacturer and distributor of high-performance scientific instruments and analytical and diagnostic solutions. The Company's segments include Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI NANO, and Bruker Energy & Supercon Technologies (BEST). Its BSI segment designs, manufactures and distributes life science tools based on magnetic resonance technology and offers automated laboratory research and development solutions in chemical research fields. Its BSI CALID segment designs, manufactures and distributes life science mass spectrometry, applied spectrometry and ion mobility spectrometry solutions, analytical and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies. BSI NANO designs, manufactures and distributes advanced x-ray instruments, atomic force microscopy instrumentation, fluorescence optical microscopy instruments, analytical tools for electron microscopes and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Bruker Q1 2026 Earnings Call Insights Highlight Strong Performance
- Performance Exceeds Expectations: Bruker's Q1 2026 reported revenue reached $823.4 million, reflecting a 2.7% year-over-year increase despite a 4.4% organic revenue decline, indicating the company's resilience in challenging conditions.
- AI-Driven Growth: The company achieved over 20% organic bookings growth in its AI-driven semiconductor metrology, SciY scientific software, and lab digitization businesses, suggesting strong market demand in these areas that could drive overall revenue recovery.
- Order Momentum: The BEST segment secured approximately $80 million in multi-year orders in Q1, while superconductors orders reached about $600 million over the last five months, demonstrating the company's ability to recover in key technology sectors.
- 2026 Outlook: Management reaffirmed the 2026 revenue guidance of $3.57 billion to $3.60 billion, expecting organic revenue growth of 1% to 2%, with a forecast for low to mid-single-digit organic revenue growth in Q2, reflecting cautious optimism about future market conditions.
See More
Bruker Q1 Earnings Exceed Expectations with Strong Guidance
- Earnings Beat: Bruker's Q1 non-GAAP EPS of $0.31 surpassed expectations by $0.08, indicating a robust profitability trend that enhances investor confidence in the company's financial health.
- Revenue Growth: The company reported Q1 revenue of $823.4 million, reflecting a 2.7% year-over-year increase and exceeding market expectations by $27.73 million, showcasing its competitive strength and sales capabilities.
- Strong Bookings: Bruker Scientific Instruments saw high-single-digit organic growth in bookings year-over-year, with a book-to-bill ratio above 1.0 for the third consecutive quarter, indicating strong market demand and a positive business outlook.
- Guidance Reaffirmed: The company reaffirmed its FY2026 revenue guidance of $3.57 to $3.60 billion, projecting a 4% to 5% year-over-year increase, with non-GAAP EPS expectations of $2.10 to $2.15, reflecting confidence in future performance.
See More
Bruker Exceeds Expectations in Q1 Financial Results
- Revenue Growth: Bruker's Q1 2026 revenue reached $823.4 million, reflecting a 2.7% year-over-year increase despite a 4.4% organic decline, demonstrating resilience amid market challenges.
- Profitability Decline: The GAAP diluted EPS for Q1 was $0.02, a significant drop from $0.11 in Q1 2025, highlighting the impact of cost pressures and market conditions on profitability.
- Strong Orders: The Bruker Scientific Instruments segment saw high single-digit percentage growth in bookings year-over-year, with a book-to-bill ratio exceeding 1.0 for the third consecutive quarter, indicating robust market demand, particularly in semiconductor and industrial research sectors.
- Financial Outlook Reaffirmed: The company reaffirmed its FY2026 revenue guidance of $3.57 to $3.60 billion, representing a 4% to 5% year-over-year increase, with non-GAAP EPS expected to grow by 15% to 17%, reflecting confidence in future growth.
See More
Bruker to Announce Q1 Earnings on May 6
- Earnings Announcement: Bruker (BRKR) is set to release its Q1 earnings on May 6 before market open, with consensus EPS estimate at $0.23, reflecting a 51.1% year-over-year decline, and revenue estimate at $795.67 million, down 0.7% year-over-year.
- Historical Performance: Over the past two years, Bruker has beaten EPS estimates 75% of the time and revenue estimates 75% of the time, indicating a consistent financial performance track record.
- Estimate Revision Trends: In the last three months, EPS estimates have seen no upward revisions and 10 downward revisions, while revenue estimates experienced 3 upward revisions and 5 downward revisions, suggesting market caution regarding the company's future performance.
- Long-term Growth Outlook: Bruker projects a 15-17% EPS growth and aims for a 250-300 basis points margin expansion by 2026, driven by cost initiatives and market recovery efforts.
See More
Bruker Corporation to Report Q1 2026 Financial Results
- Earnings Release Schedule: Bruker Corporation will report its first quarter 2026 financial results before market opening on May 6, 2026, which is expected to provide critical business trends and financial data to help investors assess the company's performance.
- Conference Call Details: The company will host a conference call and webcast at 8:00 a.m. Eastern Time, allowing investors to participate by dialing 1-888-437-2685 (U.S. toll free) or +1-412-317-6702 (international), ensuring timely access to financial information.
- Pre-registration Convenience: Bruker is enabling investors to pre-register for the conference call to expedite entry and avoid waiting, reflecting the company's commitment to enhancing investor relations and experience.
- Replay Information: A telephone replay of the conference call will be available until June 6, 2026, allowing investors who missed the live event to access important information by dialing 1-855-669-9658 (U.S. toll free) or +1-412-317-0088 (international).
See More
Bruker Spatial Biology Unveils New Platforms at AACR 2026
- New Platform Launch: Bruker Corporation unveiled cross-platform workflows linking GeoMx and CellScape at the AACR 2026 meeting, showcasing the first-of-its-kind 208-plex CellScape XR spatial proteomics datasets aimed at accelerating oncology research.
- Dataset Innovation: The newly launched 208-plex datasets, developed in collaboration with the University Medical Center Schleswig-Holstein, demonstrate the application potential of CellScape XR in tumor biology and immune contexture, enhancing research depth for clinical applications.
- PaintScape Platform: Bruker's PaintScape platform enables high-precision visualization of the 3D genome in single cells, launching the 419-plex ChromoPaint HuCL PanChromo MPX panel to help researchers understand the relationship between genome structure and disease.
- Multiomics Integration: The GeoMx DSP platform is the first to integrate spatial multiomics data across RNA pathways, proteins, and post-translational modifications, facilitating seamless connections for biomarker discovery and clinical validation.
See More
Bruker Q1 2026 Earnings Call Insights Highlight Strong Performance
- Performance Exceeds Expectations: Bruker's Q1 2026 reported revenue reached $823.4 million, reflecting a 2.7% year-over-year increase despite a 4.4% organic revenue decline, indicating the company's resilience in challenging conditions.
- AI-Driven Growth: The company achieved over 20% organic bookings growth in its AI-driven semiconductor metrology, SciY scientific software, and lab digitization businesses, suggesting strong market demand in these areas that could drive overall revenue recovery.
- Order Momentum: The BEST segment secured approximately $80 million in multi-year orders in Q1, while superconductors orders reached about $600 million over the last five months, demonstrating the company's ability to recover in key technology sectors.
- 2026 Outlook: Management reaffirmed the 2026 revenue guidance of $3.57 billion to $3.60 billion, expecting organic revenue growth of 1% to 2%, with a forecast for low to mid-single-digit organic revenue growth in Q2, reflecting cautious optimism about future market conditions.
See More
Bruker Q1 Earnings Exceed Expectations with Strong Guidance
- Earnings Beat: Bruker's Q1 non-GAAP EPS of $0.31 surpassed expectations by $0.08, indicating a robust profitability trend that enhances investor confidence in the company's financial health.
- Revenue Growth: The company reported Q1 revenue of $823.4 million, reflecting a 2.7% year-over-year increase and exceeding market expectations by $27.73 million, showcasing its competitive strength and sales capabilities.
- Strong Bookings: Bruker Scientific Instruments saw high-single-digit organic growth in bookings year-over-year, with a book-to-bill ratio above 1.0 for the third consecutive quarter, indicating strong market demand and a positive business outlook.
- Guidance Reaffirmed: The company reaffirmed its FY2026 revenue guidance of $3.57 to $3.60 billion, projecting a 4% to 5% year-over-year increase, with non-GAAP EPS expectations of $2.10 to $2.15, reflecting confidence in future performance.
See More
Bruker Exceeds Expectations in Q1 Financial Results
- Revenue Growth: Bruker's Q1 2026 revenue reached $823.4 million, reflecting a 2.7% year-over-year increase despite a 4.4% organic decline, demonstrating resilience amid market challenges.
- Profitability Decline: The GAAP diluted EPS for Q1 was $0.02, a significant drop from $0.11 in Q1 2025, highlighting the impact of cost pressures and market conditions on profitability.
- Strong Orders: The Bruker Scientific Instruments segment saw high single-digit percentage growth in bookings year-over-year, with a book-to-bill ratio exceeding 1.0 for the third consecutive quarter, indicating robust market demand, particularly in semiconductor and industrial research sectors.
- Financial Outlook Reaffirmed: The company reaffirmed its FY2026 revenue guidance of $3.57 to $3.60 billion, representing a 4% to 5% year-over-year increase, with non-GAAP EPS expected to grow by 15% to 17%, reflecting confidence in future growth.
See More
Bruker to Announce Q1 Earnings on May 6
- Earnings Announcement: Bruker (BRKR) is set to release its Q1 earnings on May 6 before market open, with consensus EPS estimate at $0.23, reflecting a 51.1% year-over-year decline, and revenue estimate at $795.67 million, down 0.7% year-over-year.
- Historical Performance: Over the past two years, Bruker has beaten EPS estimates 75% of the time and revenue estimates 75% of the time, indicating a consistent financial performance track record.
- Estimate Revision Trends: In the last three months, EPS estimates have seen no upward revisions and 10 downward revisions, while revenue estimates experienced 3 upward revisions and 5 downward revisions, suggesting market caution regarding the company's future performance.
- Long-term Growth Outlook: Bruker projects a 15-17% EPS growth and aims for a 250-300 basis points margin expansion by 2026, driven by cost initiatives and market recovery efforts.
See More
Bruker Corporation to Report Q1 2026 Financial Results
- Earnings Release Schedule: Bruker Corporation will report its first quarter 2026 financial results before market opening on May 6, 2026, which is expected to provide critical business trends and financial data to help investors assess the company's performance.
- Conference Call Details: The company will host a conference call and webcast at 8:00 a.m. Eastern Time, allowing investors to participate by dialing 1-888-437-2685 (U.S. toll free) or +1-412-317-6702 (international), ensuring timely access to financial information.
- Pre-registration Convenience: Bruker is enabling investors to pre-register for the conference call to expedite entry and avoid waiting, reflecting the company's commitment to enhancing investor relations and experience.
- Replay Information: A telephone replay of the conference call will be available until June 6, 2026, allowing investors who missed the live event to access important information by dialing 1-855-669-9658 (U.S. toll free) or +1-412-317-0088 (international).
See More
Bruker Spatial Biology Unveils New Platforms at AACR 2026
- New Platform Launch: Bruker Corporation unveiled cross-platform workflows linking GeoMx and CellScape at the AACR 2026 meeting, showcasing the first-of-its-kind 208-plex CellScape XR spatial proteomics datasets aimed at accelerating oncology research.
- Dataset Innovation: The newly launched 208-plex datasets, developed in collaboration with the University Medical Center Schleswig-Holstein, demonstrate the application potential of CellScape XR in tumor biology and immune contexture, enhancing research depth for clinical applications.
- PaintScape Platform: Bruker's PaintScape platform enables high-precision visualization of the 3D genome in single cells, launching the 419-plex ChromoPaint HuCL PanChromo MPX panel to help researchers understand the relationship between genome structure and disease.
- Multiomics Integration: The GeoMx DSP platform is the first to integrate spatial multiomics data across RNA pathways, proteins, and post-translational modifications, facilitating seamless connections for biomarker discovery and clinical validation.
See More
